Matuzumab (formerly EMD 72000) was a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it has undergone phase II clinical trials for the treatment of colorectal, lung, esophageal and stomach cancer early in the 2000s.

PropertyValue
dbpedia-owl:abstract
  • Matuzumab (auch als EMD72000 bezeichnet), ist ein therapeutischer, weitgehend humanisierter, monoklonaler Antikörper vom Typ IgG1, gegen den EGF-Rezeptor (Epidermal Growth Factor Receptor), zur Bekämpfung von Krebstumoren. Matuzumab ist eine Entwicklung der Merck KGaA. Die Weiterentwicklung von Matuzumab stellte Merck 2007 ein. Matuzumab ist im Gegensatz zu dem bereits für verschiedene Krebsarten zugelassenen Cetuximab, welches ein chimärer Antikörper mit Proteinanteilen aus Maus und Mensch ist, fast vollständig humanen Ursprungs. Es ist deshalb für Patientien mit einer besseren Verträglichkeit zu rechnen.
  • Matuzumab (formerly EMD 72000) was a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it has undergone phase II clinical trials for the treatment of colorectal, lung, esophageal and stomach cancer early in the 2000s. In August 2007, Merck Serono announced that the preliminary results of the colorectal cancer study were less than promising, and that further trials for treating this type of cancer may be abandoned. In February 2008, the development was halted because of disappointing study results.
  • Il matuzumab o 72.000 EMD è stato anticorpo monoclonale umanizzato per il trattamento del cancro. Esso si lega al recettore del fattore di crescita epidermico con alta affinità. Sviluppato inizialmente dalla Merck Serono in collaborazione con Takeda Pharmaceutical, ha subito diversi studi clinici di fase II per il trattamento del tumore del colon-retto, del polmone, dell'esofago e dello stomaco fino a tutto l'inizio del 2000. Poi nell'agosto del 2007, la Merck Serono ha annunciato che i risultati preliminari dello studio sul cancro colon-rettale sono stati inferiori alle promesse, e che perciò le ulteriori sperimentazioni su questo tipo di tumore saranno abbandonate. Nel febbraio 2008, lo sviluppo è stato interrotto definitivamente a causa dei risultati deludenti prodotti.
dbpedia-owl:atcPrefix
  • none
dbpedia-owl:casNumber
  • 339186-68-4
dbpprop:atcPrefix
  • none
dbpprop:bioavailability
  • N/A
dbpprop:casNumber
  • 339186 (xsd:integer)
dbpprop:legalStatus
  • clinical development failed
dbpprop:mabType
  • mab
dbpprop:source
  • zu
dbpprop:target
dbpprop:type
  • mab
dbpprop:verifiedrevid
  • 400279294 (xsd:integer)
dbpprop:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Matuzumab (auch als EMD72000 bezeichnet), ist ein therapeutischer, weitgehend humanisierter, monoklonaler Antikörper vom Typ IgG1, gegen den EGF-Rezeptor (Epidermal Growth Factor Receptor), zur Bekämpfung von Krebstumoren. Matuzumab ist eine Entwicklung der Merck KGaA. Die Weiterentwicklung von Matuzumab stellte Merck 2007 ein.
  • Il matuzumab o 72.000 EMD è stato anticorpo monoclonale umanizzato per il trattamento del cancro. Esso si lega al recettore del fattore di crescita epidermico con alta affinità. Sviluppato inizialmente dalla Merck Serono in collaborazione con Takeda Pharmaceutical, ha subito diversi studi clinici di fase II per il trattamento del tumore del colon-retto, del polmone, dell'esofago e dello stomaco fino a tutto l'inizio del 2000.
  • Matuzumab (formerly EMD 72000) was a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it has undergone phase II clinical trials for the treatment of colorectal, lung, esophageal and stomach cancer early in the 2000s.
rdfs:label
  • Matuzumab
  • Matuzumab
  • Matuzumab
owl:sameAs
foaf:page
is dbpedia-owl:wikiPageRedirects of
is owl:sameAs of
is foaf:primaryTopic of